Targeting dormant leukaemia cells
Nature
May 12, 2008
A new role for a protein involved in leukaemia is described in Nature this week; the research demonstrates its potential as a therapeutic target to eradicate dormant leukaemia-initiating cells.
The promyelocytic leukaemia protein (PML) tumour suppressor is known to be involved in the development of some forms of leukaemia. Pier Paolo Pandolfi and colleagues identify a new and unexpected role for PML in the maintenance of both haematopoietic stem cells and leukaemia-initiating cells. They demonstrate, in mice, that targeting the protein with arsenic trioxide eliminates the cancer-initiating cells, thought to be resistant to chemotherapy and other therapies.
The team believes that their results present a new pharmacological approach to target cells that are missed by other therapies and therefore lead to disease relapse.
doi: 10.1038/nature07016
Research highlights
-
Nov 13
Environment: Value of national parks’ impact on mental health estimatedNature Communications
-
Nov 12
Ecology: Lost deer-like species ‘rediscovered’Nature Ecology & Evolution
-
Nov 12
Geoscience: Earth’s mantle motion has kept Nile stable for 30 million yearsNature Geoscience
-
Nov 8
Biology: Arctic sea ice loss may facilitate disease spread in marine mammalsScientific Reports
-
Nov 7
Climate science: Identifying California’s methane super-emittersNature
-
Nov 5
Planetary science: First results from Voyager 2’s interstellar journeyNature Astronomy
